FGFR2 alterations in endometrial carcinoma

Fibroblast growth factor receptor 2 (FGFR2) is a tyrosine kinase receptor involved in many biological processes such as embryogenesis, adult tissue homeostasis and cell proliferation. Mutations in FGFR2 have been reported in up to 10–12% of endometrial carcinomas identical to those found in congenital craniofacial disorders. Inhibition of FGFR2 could be a new therapeutic target in endometrial carcinoma. FGFR2 immunostaining was assessed in three tissue microarrays: one constructed from paraffin-embedded blocks of 60 samples of normal endometrium in different phases of menstrual cycle, and two tissue microarrays containing endometrial carcinoma samples (95 and 62 cases). FGFR2 expression was correlated with stage, histological type and grade as well as with immunostaining of PTEN, RASSF1A, estrogen and progesterone receptors, KI67, Cyclin D1, STAT-3 and SPRY2. FGFR2 mutations were assessed by PCR and direct sequencing, with DNA obtained from 31 paraffin-embedded endometrial carcinoma samples. In normal endometrium, FGFR2 expression was higher in the secretory than in the proliferative phase (P=0.001), with an inverse correlation with Ki67 (P=0.00032), suggesting a tumor-suppressor role for FGFR2 in normal endometrium. Cytoplasmic expression of FGFR2 was higher in endometrial carcinoma when compared with the atrophic endometrium from the same patients (P=0.0283), but was lower in comparison with normal endometrium from women in the menstrual cycle. Interestingly, nuclear staining was observed in some cases, and it was less frequent in endometrial carcinoma when compared with the adjacent atrophic endometrium (P=0.0465). There were no statistical differences when comparing superficial and myoinvasive endometrial carcinoma samples. Endometrioid endometrial carcinomas showed higher expression of FGFR2 than nonendometrioid endometrial carcinomas (fold change 2.56; P=0.0015). Grade III endometrioid endometrial carcinomas showed decreased FGFR2 expression when compared with grade II endometrioid endometrial carcinomas (P=0.0055). No differences were found regarding pathological stage. Two missense mutations of FGFR2 gene were detected in exons 6 and 11 (S252W and N549K, respectively; 6.45%). Results support the hypothesis that FGFR2 has a dual role in the endometrium, by inhibiting cell proliferation in normal endometrium during the menstrual cycle, but acting as an oncogene in endometrial carcinoma.

[1]  E. Lerma,et al.  Uterine papillary serous adenocarcinoma. A 10‐case study of p53 and c‐erbB‐2 expression and DNA content , 1994, Cancer.

[2]  N. Eritja,et al.  Promoter hypermethylation and reduced expression of RASSF1A are frequent molecular alterations of endometrial carcinoma , 2008, Modern Pathology.

[3]  X. Matías-Guiu,et al.  CTNNB1 mutations and beta-catenin expression in endometrial carcinomas. , 2002, Human pathology.

[4]  X. Matías-Guiu,et al.  Beta- and gamma-catenin expression in endometrial carcinoma. Relationship with clinicopathological features and microsatellite instability. , 2001, Virchows Archiv : an international journal of pathology.

[5]  J. Herman,et al.  Abnormalities of the APC/β-catenin pathway in endometrial cancer , 2002, Oncogene.

[6]  J. Cigudosa,et al.  Cyclin D1 gene (CCND1) mutations in endometrial cancer , 2003, Oncogene.

[7]  J. V. Bokhman.  Two pathogenetic types of endometrial carcinoma. , 1983, Gynecologic oncology.

[8]  Kristian Cibulskis,et al.  Drug-sensitive FGFR2 mutations in endometrial carcinoma , 2008, Proceedings of the National Academy of Sciences.

[9]  M. Katoh.  Cancer genomics and genetics of FGFR2 (Review). , 2008, International journal of oncology.

[10]  X. Matías-Guiu,et al.  K‐ras mutations in endometrial carcinomas with microsatellite instability , 2001, The Journal of pathology.

[11]  N. Turner,et al.  Fibroblast growth factor signalling: from development to cancer , 2010, Nature Reviews Cancer.

[12]  J. Herman,et al.  Abnormalities of E‐ and P‐cadherin and catenin (β‐, γ‐catenin, and p120ctn) expression in endometrial cancer and endometrial atypical hyperplasia , 2003 .

[13]  Michael K. Wendt,et al.  Transforming Growth Factor-β-Induced Epithelial-Mesenchymal Transition Facilitates Epidermal Growth Factor-Dependent Breast Cancer Progression , 2010, Oncogene.

[14]  N. Eritja,et al.  Loss of Heterozygosity in Endometrial Carcinoma , 2008, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[15]  M. Rue,et al.  Abnormalities in the NF-kappaB family and related proteins in endometrial carcinoma. , 2004, The Journal of pathology.

[16]  J. Herman,et al.  Abnormalities of E- and P-cadherin and catenin (beta-, gamma-catenin, and p120ctn) expression in endometrial cancer and endometrial atypical hyperplasia. , 2003, The Journal of pathology.

[17]  T. Shibata,et al.  TGF-β regulates isoform switching of FGF receptors and epithelial–mesenchymal transition , 2011, The EMBO journal.

[18]  E. Jabs,et al.  Clinical spectrum of fibroblast growth factor receptor mutations , 1999, Human mutation.

[19]  D. Birnbaum,et al.  BEK and FLG, two receptors to members of the FGF family, are amplified in subsets of human breast cancers. , 1991, Oncogene.

[20]  X. Matías-Guiu,et al.  CTNNB1 mutations and β-catenin expression in endometrial carcinomas , 2002 .

[21]  J. Valls,et al.  Promoter hypermethylation and expression of sprouty 2 in endometrial carcinoma. , 2011, Human pathology.

[22]  D. Bar-Sagi,et al.  Modulation of signalling by Sprouty: a developing story , 2004, Nature Reviews Molecular Cell Biology.

[23]  Matthew A Powell,et al.  Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation. , 2008, Cancer research.

[24]  Erik Meulmeester,et al.  The dynamic roles of TGF‐β in cancer , 2011, The Journal of pathology.

[25]  J. G. Park,et al.  Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers. , 2001, Cancer research.

[26]  M. Rue,et al.  FLIP is frequently expressed in endometrial carcinoma and has a role in resistance to TRAIL-induced apoptosis , 2005, Laboratory Investigation.

[27]  X. Matías-Guiu,et al.  Microsatellite instability in endometrial carcinomas: clinicopathologic correlations in a series of 42 cases. , 1998, Human pathology.

[28]  A. García,et al.  Molecular pathology of endometrial hyperplasia and carcinoma. , 2001, Human pathology.

[29]  Andrew D. Yates,et al.  Somatic mutations of the protein kinase gene family in human lung cancer. , 2005, Cancer research.

[30]  P. Pollock,et al.  Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes , 2007, Oncogene.

[31]  W. Willett,et al.  A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer , 2007, Nature Genetics.

[32]  X. Matías-Guiu,et al.  PIK3CA gene mutations in endometrial carcinoma: correlation with PTEN and K-RAS alterations. , 2006, Human pathology.

[33]  J. Cigudosa,et al.  Differential gene expression profile in endometrioid and nonendometrioid endometrial carcinoma: STK15 is frequently overexpressed and amplified in nonendometrioid carcinomas. , 2003, Cancer research.

[34]  J. Herman,et al.  Abnormalities of the APC/beta-catenin pathway in endometrial cancer. , 2002, Oncogene.

[35]  J. Thiery,et al.  Alternative splicing in fibroblast growth factor receptor 2 is associated with induced epithelial-mesenchymal transition in rat bladder carcinoma cells. , 1994, Molecular biology of the cell.

[36]  G. Guy,et al.  Sprouty and cancer: the first terms report. , 2006, Cancer letters.

[37]  Kathleen R. Cho,et al.  Microsatellite instability in endometrial carcinoma. , 1994, Oncogene.

[38]  X. Matías-Guiu,et al.  PTEN mutations in endometrial carcinomas: a molecular and clinicopathologic analysis of 38 cases. , 2000, Human pathology.

[39]  M. Rue,et al.  Abnormalities in the NF‐κB family and related proteins in endometrial carcinoma , 2004 .